 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
24 News |  |
- | fletikumab (NNC109-0012) / Novo Nordisk, fezakinumab (ILV-094) / Pfizer
Review, Journal: The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. (Pubmed Central) - Oct 11, 2019
All IL-20 family members utilize the Janus kinase signaling pathway and are therefore potentially inhibited by drugs targeting these enzymes. Effects and adverse effects in ongoing clinical trials with inhibitors of IL-22 and the IL-22RA1 subunit and recombinant IL-22 fusion proteins will possibly provide important information about the IL-20 subfamily of cytokines in the future.
- | fletikumab (NNC109-0012) / Novo Nordisk
Phase classification: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Sep 5, 2018
P2b, N=298, Terminated, Sponsor: Novo Nordisk A/S
Effects and adverse effects in ongoing clinical trials with inhibitors of IL-22 and the IL-22RA1 subunit and recombinant IL-22 fusion proteins will possibly provide important information about the IL-20 subfamily of cytokines in the future. Phase classification: P2 --> P2b
- | fletikumab (NNC109-0012) / Novo Nordisk
Phase classification: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Sep 5, 2018
P2b, N=239, Terminated, Sponsor: Novo Nordisk A/S
Phase classification: P2 --> P2b Phase classification: P2 --> P2b
- fletikumab (NNC109-0012) / Novo Nordisk
Phase classification: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects (clinicaltrials.gov) - Feb 11, 2017
P1, N=55, Terminated, Sponsor: Novo Nordisk A/S
Phase classification: P2 --> P2b Phase classification: P1/2 --> P1
- fletikumab (NNC109-0012) / Novo Nordisk
Trial termination: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Nov 20, 2014
P2, N=298, Terminated, Sponsor: Novo Nordisk A/S
Phase classification: P1/2 --> P1 Active, not recruiting --> Terminated
- fletikumab (NNC109-0012) / Novo Nordisk
Trial termination: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Nov 20, 2014
P2, N=239, Terminated, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- fletikumab (NNC109-0012) / Novo Nordisk
Trial primary completion date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Aug 21, 2014
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Terminated Trial primary completion date: Feb 2015 --> Nov 2014
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment closed, Trial primary completion date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Aug 21, 2014
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2015 --> Nov 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Nov 2014
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment change, Trial withdrawal, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Aug 15, 2014
P2, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Nov 2014 N=42 --> 0 | Not yet recruiting --> Withdrawn
- fletikumab (NNC109-0012) / Novo Nordisk
Trial initiation date, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jul 1, 2014
P2, N=42, Not yet recruiting, Sponsor: Novo Nordisk A/S
N=42 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Mar 2014 --> Sep 2014
- fletikumab (NNC109-0012) / Novo Nordisk
Trial primary completion date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - May 19, 2014
P2, N=268, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Mar 2014 --> Sep 2014 Trial primary completion date: Sep 2015 --> Dec 2015
- fletikumab (NNC109-0012) / Novo Nordisk
Trial completion date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - May 19, 2014
P2, N=268, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2015 --> Dec 2015 Trial completion date: Sep 2015 --> Dec 2015
- fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 25, 2014
P2, N=42, Recruiting, Sponsor: Novo Nordisk A/S
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment open, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 23, 2014
P2, N=42, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Sep 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- ||| fletikumab (NNC109-0012) / Novo Nordisk
Enrollment closed: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Dec 3, 2013
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment open: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Oct 24, 2012
P2, N=268, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Suspended --> Recruiting
- ||| fletikumab (NNC109-0012) / Novo Nordisk
Trial initiation date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Sep 6, 2012
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk
Suspended --> Recruiting Initiation date: Jul 2012 --> Oct 2012
- ||||| fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Jul 8, 2012
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk
- | fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Jul 8, 2012
P2, N=268, Recruiting, Sponsor: Novo Nordisk A/S
- |||| fletikumab (NNC109-0012) / Novo Nordisk
Trial completion: Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 8, 2012
P2, N=67, Completed, Sponsor: Novo Nordisk
Initiation date: Jul 2012 --> Oct 2012 Active, not recruiting --> Completed